Search clinical trials for: AERAS-404 (mcg H4/nmol IC31)

Total 8 results

Aeras
Statens Serum Institut

Completed

A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 (C-011-404) (C-011-404)

Tuberculosis

South Africa
Aeras
Sanofi Pasteur, a Sanofi Company

Completed

Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents

Tuberculosis

South Africa
Aeras
Sanofi Pasteur, a Sanofi Company; Statens Serum Institut; HIV Vaccine Trials...

Completed

Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents

Tuberculosis

South Africa
Aeras
Statens Serum Institut

Completed

A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS-404 Administered as Different Amounts of Antigen and Adjuvant Combinations in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection

Tuberculosis

Sweden
Aeras
Sanofi Pasteur, a Sanofi Company

Completed

A Study for Safety and Immunogenicity of BCG and AERAS-404 in HIV-Negative, TB-Negative, BCG-Naive Adults (C-013-404)

Tuberculosis

Switzerland
Aeras
National Institute of Allergy and Infectious Diseases (NIAID); Sanofi Pasteur... and other collaborators

Completed

Phase 1/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants (C-015-404)

Tuberculosis

South Africa
Aeras
Statens Serum Institut

Completed

A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 Administered in Adults

Tuberculosis

Finland
Aeras

Completed

A Leukapheresis Study for Immune Responses in Healthy US Adults Who Receive BCG Vaccination Followed by Boosting With AERAS-402 (C-021-402)

Tuberculosis

3

Subscribe